NASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis $52.98 -0.59 (-1.10%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get RxSight alerts: Email Address About RxSight Stock (NASDAQ:RXST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RxSight alerts:Sign Up Key Stats Today's Range$52.77▼$53.6450-Day Range$40.78▼$56.5652-Week Range$20.66▼$66.54Volume1.36 million shsAverage Volume485,738 shsMarket Capitalization$1.96 billionP/E RatioN/ADividend YieldN/APrice Target$60.14Consensus RatingBuy Company OverviewRxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More… The election trade you can't lose (Ad)Politics is an unpredictable game. But no matter what happens in the next few months... There's one thing that can't be stopped by anything: Dividends.Download my Dividend Calendar here RxSight Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 67th PercentileRxSight scored higher than 67% of companies evaluated by MarketBeat, and ranked 358th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRxSight has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRxSight has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about RxSight's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($0.81) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -42.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -42.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 11.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.09% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in RxSight has recently decreased by 16.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.09% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in RxSight has recently decreased by 16.42%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.80 News SentimentRxSight has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for RxSight this week, compared to 3 articles on an average week.Search Interest8 people have searched for RXST on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $939,350.00 in company stock.Percentage Held by InsidersOnly 9.36% of the stock of RxSight is held by insiders.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Stock News HeadlinesHere's Why We're Not At All Concerned With RxSight's (NASDAQ:RXST) Cash Burn SituationSeptember 18 at 7:59 AM | finance.yahoo.comRxSight (NASDAQ:RXST) Earns Buy Rating from Needham & Company LLCSeptember 16, 2024 | americanbankingnews.comForget Trump and KamalaForget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.September 20, 2024 | Investors Alley (Ad)RxSight, Inc. (NASDAQ:RXST) Receives $60.14 Average PT from AnalystsSeptember 16, 2024 | americanbankingnews.comRxSight’s Growth Trajectory: A Buy Recommendation on Strong Revenue Prospects and International ExpansionSeptember 14, 2024 | markets.businessinsider.comRxSight’s Growth Potential and Market Expansion Drive Buy RatingSeptember 6, 2024 | markets.businessinsider.comRxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare ConferencesAugust 22, 2024 | globenewswire.comInvesting In The Future Of Cataract Surgery: The RxSight AdvantageAugust 13, 2024 | seekingalpha.comSee More Headlines RXST Stock Analysis - Frequently Asked Questions How have RXST shares performed this year? RxSight's stock was trading at $40.32 at the beginning of 2024. Since then, RXST stock has increased by 31.4% and is now trading at $52.98. View the best growth stocks for 2024 here. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) announced its quarterly earnings data on Monday, August, 5th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. The firm's revenue was up 67.6% on a year-over-year basis. When did RxSight IPO? RxSight (RXST) raised $125 million in an IPO on Friday, July 30th 2021. The company issued 7,350,000 shares at a price of $16.00-$18.00 per share. Who are RxSight's major shareholders? RxSight's top institutional shareholders include Driehaus Capital Management LLC (1.91%), Baillie Gifford & Co. (0.97%), Marshall Wace LLP (0.88%) and William Blair Investment Management LLC (0.67%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Julie Andrews, Robert Keith Warner, William J Phd Link, Shelley B Thunen, Jesse Anderson Corley and Shweta Maniar. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/05/2024Today9/20/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Ophthalmic goods Sub-IndustryMedical Equipment Current SymbolNASDAQ:RXST CUSIPN/A CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$60.14 High Stock Price Target$73.00 Low Stock Price Target$36.00 Potential Upside/Downside+13.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,610,000.00 Net Margins-31.92% Pretax Margin-31.91% Return on Equity-19.33% Return on Assets-17.24% Debt Debt-to-Equity RatioN/A Current Ratio14.34 Quick Ratio13.34 Sales & Book Value Annual Sales$115.18 million Price / Sales17.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book11.85Miscellaneous Outstanding Shares36,988,000Free Float33,526,000Market Cap$1.96 billion OptionableOptionable Beta1.22 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:RXST) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.